Evidence map›Paper›PMID 26078269›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

Tick Salivary Sialostatin L Represses the Initiation of Immune Responses by Targeting IRF4-Dependent Transcription in Murine Mast Cells.

Matthias Klein, Till-Julius Brühl, Valérie Staudt, Sebastian Reuter, Nadine Grebe, Bastian Gerlitzki, Markus Hoffmann, Toszka Bohn, Alexander Ulges, Natascha Stergiou and 18 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Ethyl ferulate attenuates allergic asthma via inhibiting macrophage M2 polarization through STAT6/IRF4 pathway.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Article
  3. Acquired tick resistance inInfection and immunity · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Changing the Recipe: Pathogen Directed Changes in Tick Saliva Components.International journal of environmental research and public health · 2021
    Review
  9. Review
  10. Immunomodulatory Proteins in Tick Saliva From a Structural Perspective.Frontiers in cellular and infection microbiology · 2021
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Frontiers in immunology · 2017
    Review
  19. Review
  20. For Whom the Bell Tolls (and Nods): Spit-acular Saliva.Current tropical medicine reports · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 7 institutions in 5 countries.

Matthias KleinInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Till-Julius BrühlInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Valérie StaudtInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Sebastian ReuterIII. Medical Clinic, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Nadine GrebeInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Bastian GerlitzkiInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Markus HoffmannInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Toszka BohnInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Alexander UlgesInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Natascha StergiouInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Jos de GraafTranslational Oncology, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany;
Martin LöwerTranslational Oncology, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany;
Christian TaubeDepartment of Pulmonology, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands;
Marc BeckerInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Tobias HainInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Sarah DietzenInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Michael StassenInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Magdalena HuberInstitut für Medizinische Mikrobiologie und Krankenhaushygiene, 35043 Marburg, Germany;
Michael LohoffInstitut für Medizinische Mikrobiologie und Krankenhaushygiene, 35043 Marburg, Germany;
Andrezza Campos ChagasLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852;
John AndersenLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852;
Jan KotálInstitute of Parasitology, Biology Centre of the Academy of Sciences of the Czech Republic, 37005 České Budějovice, Czech Republic; and.
Helena LanghansováInstitute of Parasitology, Biology Centre of the Academy of Sciences of the Czech Republic, 37005 České Budějovice, Czech Republic; and Faculty of Science, University of South Bohemia, 37005 České Budějovice, Czech Republic.
Jan KopeckýInstitute of Parasitology, Biology Centre of the Academy of Sciences of the Czech Republic, 37005 České Budějovice, Czech Republic; and Faculty of Science, University of South Bohemia, 37005 České Budějovice, Czech Republic.
Hansjörg SchildInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Michalis KotsyfakisInstitute of Parasitology, Biology Centre of the Academy of Sciences of the Czech Republic, 37005 České Budějovice, Czech Republic; and.
Edgar SchmittInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany;
Tobias BoppInstitute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany; boppt@uni-mainz.de.
Johannes Gutenberg University Mainz · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DECzech Academy of Sciences, Biology Centre · CZInstitut für Medizinische Informatik, Biometrie und Epidemiologie · DENational Institutes of Health · USLeiden University Medical Center · NLUniversity of South Bohemia in České Budějovice · CZ

Funding

Vector-Borne Diseases: Molecular Mechanisms in Vector-Host InteractionsZIAAI001012 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RIBEIRO, JOSE · 2009 to 2025
$9.4M
Vector-Borne Diseases: Molecular Mechanisms in Vector-Host InteractionsZ01AI001012 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI RIBEIRO, JOSE · 2007 to 2008
$1.5M
Intramural NIH HHS Z01 AI001012
6 · The paper itself

Abstract

Coevolution of ticks and the vertebrate immune system has led to the development of immunosuppressive molecules that prevent immediate response of skin-resident immune cells to quickly fend off the parasite. In this article, we demonstrate that the tick-derived immunosuppressor sialostatin L restrains IL-9 production by mast cells, whereas degranulation and IL-6 expression are both unaffected. In addition, the expression of IL-1β and IRF4 is strongly reduced in the presence of sialostatin L. Correspondingly, IRF4- or IL-1R-deficient mast cells exhibit a strong impairment in IL-9 production, demonstrating the importance of IRF4 and IL-1 in the regulation of the Il9 locus in mast cells. Furthermore, IRF4 binds to the promoters of Il1b and Il9, suggesting that sialostatin L suppresses mast cell-derived IL-9 preferentially by inhibiting IRF4. In an experimental asthma model, mast cell-specific deficiency in IRF4 or administration of sialostatin L results in a strong reduction in asthma symptoms, demonstrating the immunosuppressive potency of tick-derived molecules.

Indexed as

AnimalsAsthmaBinding SitesCell DegranulationCystatinsGene Expression RegulationHost-Parasite InteractionsImmunity, InnateImmunosuppressive AgentsInterferon Regulatory Factor-4Interferon Regulatory FactorsInterleukin-1betaInterleukin-6Interleukin-9Mast CellsMiceCystatinsImmunosuppressive AgentsInterferon Regulatory Factor-4Interferon Regulatory FactorsInterleukin-1betaInterleukin-6Interleukin-9Receptors, Interleukin-1sialostatin L, Ixodes scapularis

Identifiers

PMID26078269
PMCPMC4841271
OpenAlexW1556714283

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.